Amgen Shortens Epogen, Procrit Shelf-lives Following Recall
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm is working with vial manufacturers to determine the cause of the delamination.
You may also be interested in...
Does Two Make A Trend? 3SBio Joins U.S.-listed Chinese Firms Going Private
On the heels of ShangPharma, 3SBio’s move highlights depressed valuation for Chinese companies. The large premium should seal the deal for the company with a growing pipeline and revenues, analysts say.
After Brazil Onto China? Amgen Unveils Emerging Market Strategy
The world's largest biotech company Amgen Inc. aims to triple sales from emerging markets in five years through potential acquisitions and licensing back rights to current products, the company said during an April 21 business review meeting. Amgen's recent purchase of privately held Bergamo of Brazil for roughly $215 million, and its reacquisition of Brazilian rights to certain Amgen products from Mantecorp, indicate more such deals are on the way, analysts say
After Brazil Onto China? Amgen Unveils Emerging Market Strategy
The world's largest biotech company Amgen Inc. aims to triple sales from emerging markets in five years through potential acquisitions and licensing back rights to current products, the company said during an April 21 business review meeting. Amgen's recent purchase of privately held Bergamo of Brazil for roughly $215 million, and its reacquisition of Brazilian rights to certain Amgen products from Mantecorp, indicate more such deals are on the way, analysts say